SSG
CGON icon

Summit Securities Group’s CG Oncology CGON Stock Holding History

Summit Securities Group’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-163
Closed -$3.99K – 1125
2025
Q1 		$3.99K Buy
+163
New +$4.58K ﹤0.01% 627

Other funds holding CGON

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Summit Securities Group's CGON Position: Q2 2025 in Review

Summit Securities Group sold out of CG Oncology (CGON) in Q2 2025, closing a stake of 163 shares — an estimated $3.99K sold.

Summit Securities Group first reported a position in CGON in Q1 2025 and held it in 1 quarter. The position peaked at $3.99K in Q1 2025. 162 funds tracked by Wall St. Rank hold CGON as of Q2 2025.

  • Summit Securities Group reported no remaining CG Oncology position as of Q2 2025 after selling out during the quarter.
  • Summit Securities Group sold 163 CG Oncology shares in Q2 2025, an estimated $3.99K.
  • Summit Securities Group first reported a position in CG Oncology in Q1 2025 and held it in 1 quarter.
  • Summit Securities Group's CG Oncology position peaked at $3.99K in Q1 2025.
  • 162 funds tracked by Wall St. Rank held CG Oncology as of Q2 2025.

Based on Summit Securities Group's 13F filing for Q2 2025, filed 12 Aug 2025.